2 recruiting, 1 completed, 1 not yet recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Completed 1, Not yet recruiting 1 |
Follow Cilastatin: new trials by email Literature Review of Cilastatin trials Research Report on Cilastatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Efficacy and Safety of (Meropenem + Colistin) Versus (Imipenem/Cilastatin + Tigecycline) on Eradication of Multi-Drug Resistance Bacteria "Imipenem/cilastatin" and "Tigecycline", "colistin" and "meropenem" - MDR Bacteria | Phase 2 | Not yet recruiting | Ain Shams University | 60 | 2026-04-01 | 2026-04-13 |
| Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin Cilastatin Sodium, Placebo-Saline - Acute Kidney Injury | Phase 2 | Recruiting | Matthew James | 698 | 2025-07-16 | 2026-11-13 |
| A Double-blind Non Inferiority Clinical Trial to Compare the Nephroprotection of Cilastatn Versus Thiosulfate in Patients Undergoing Debulking Surgery With Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Cisplatin. cilastatine, tiosulfate - Debulking Surgery for Ovarian Cancer, Acute Kidney Injury | Phase 2 | Recruiting | Hospital General Universitario Gregorio Marañon | 90 | 2025-02-21 | 2025-11-14 |
| Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003) Relebactam 250 mg, Relebactam 125 mg, imipenem/cilastatin 500 mg - Urinary Tract Infections, Pyelonephritis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 302 | 2012-05-16 | 2019-05-24 |
Acute Kidney Injury (2) · Pyelonephritis (1) · Urinary Tract Infections (1) · Urologic Diseases (1)
Ain Shams University (1) · Hospital General Universitario Gregorio Marañon (1) · Matthew James (1) · Merck Sharp & Dohme LLC (1)
Canada (1) · Egypt (1) · Spain (1)